Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $19.5714.

Several brokerages recently commented on ADPT. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. TD Cowen boosted their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. BTIG Research restated a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Finally, Morgan Stanley dropped their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th.

Adaptive Biotechnologies Stock Performance

Shares of ADPT opened at $16.70 on Tuesday. Adaptive Biotechnologies has a one year low of $9.90 and a one year high of $20.76. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -50.61 and a beta of 2.16. The stock has a 50 day moving average price of $14.22 and a 200 day moving average price of $15.65.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. During the same period in the previous year, the business earned ($0.20) earnings per share. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. On average, analysts predict that Adaptive Biotechnologies will post -0.48 earnings per share for the current year.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Susan Bobulsky sold 11,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $18.00, for a total value of $198,000.00. Following the completion of the sale, the insider directly owned 416,775 shares in the company, valued at $7,501,950. This represents a 2.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kyle Piskel sold 3,115 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $13.04, for a total value of $40,619.60. Following the completion of the sale, the chief financial officer owned 256,725 shares of the company’s stock, valued at approximately $3,347,694. The trade was a 1.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,771,436 shares of company stock valued at $24,075,997 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

Institutional Trading of Adaptive Biotechnologies

Several large investors have recently added to or reduced their stakes in ADPT. Westfield Capital Management Co. LP purchased a new stake in Adaptive Biotechnologies in the 4th quarter valued at $65,942,000. Price T Rowe Associates Inc. MD grew its holdings in Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after buying an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares during the period. Invesco Ltd. grew its holdings in shares of Adaptive Biotechnologies by 248.8% during the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after purchasing an additional 2,216,595 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Adaptive Biotechnologies by 544.0% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after purchasing an additional 2,062,282 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.